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ABSTRACT 
Objective: CYP1A1 involved in biotransformation of carcinogenic polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic 
amines/amides (HAAs) and results in electrophilic reactive intermediates that leads to toxicity and cancer, thus influencing the fields of cancer 
research.Benzothiazole and its analogs are known for their anti-tumor activity because they act as potent aryl hydrocarbon receptor (AhR) agonist 
thus binds AhR and results in induction of CYP1A1 which forms DNA adduct and leads to cell death by activation of apoptotic mechanism. The main 
aim of this study is to extrapolate the relationship between nsSNPs of CYP1A1 and their effects in Benzothiazoles binding capability. 
Methods: Computational analysis of deleterious mutations in CYP1A1 and their impact on its structure were as well as altered drug response to 
Benzothiazoles based drug DF 203, NSC 674495 were studied. Furthermore molecular dynamics simulation (MDS) approach was conducted to 
investigate conformational changes in the mutant protein structure with respect to its native conformation. 
Results: Our studies revealed that 6 deleterious nsSNPs CYP1A1 have the impact on structural stability based on secondary structural patterns and 
molecular dynamics and altered drug response was seen in nsSNP rs2229150 (R93W) for the drug 2-(4-amino-3-methylphenyl) benzothiazole (DF 
203, NSC 674495). 
Conclusion: Our study would be helpful to understand the nsSNP effect on CYP1A1 which in turn leads to carcinogenesis as well as Benzothiazole 
(DF-203) binding affinity and designing individualized therapeutic treatments. 
Keywords: CYP1A1, nsSNPs, Molecular dynamics, Cancer, 2-(4-Amino-3-methylphenyl) benzothiazole. 
 
INTRODUCTION 
Single nucleotide polymorphism in Cytochrome P450 (CYP) 
enzymes play a vital role in xenobiotic metabolism can modulate the 
individual susceptibility to environmental contaminants exposure 
and the associated risk for cancer development [1]. CYP1A1 is one of 
the major gene among 57 functional genes of CYP gene family, is 
involved in biotransformation of procarcinogenic compounds as 
polyaromatic hydrocarbons (PAH’s) and aromatic amines found in 
cigarette smoke to carcinogen by monooxygenation [2, 3]. CYP1A1 
encodes aryl hydrocarbon hydrolase (AHH), an enzyme involved in 
the production of reactive epoxide intermediates from 
environmental contaminants such as polycyclic aromatic 
hydrocarbons [PAHs], polyhalogenated aromatic hydrocarbons 
(PHAHs) and steroid hormones that might increase the risk of 
oxidative stress and cancer. Several SNPs have been identified in 
CYP1A1, some of which lead to a more highly inducible AHH activity 
[4, 5]. Nonsynonymous single nucleotide polymorphisms (nsSNPs) 
in the gene coding regions generally considered as genetic variations 
and were linked to various human inherited diseases [6]. SNP at 
4,887 position of exon 7 results in a aminoacid change of isoleucine 
to valine (Ile to Val) [7].This amino acid variation is associated with 
CYP1A1 induction and increased AHH enzyme activity that might 
cause higher rates of carcinogen activation. So individuals with the 
variant CYP1A1 gene (Val) may be more susceptible to xenobiotic 
carcinogens and health risk [8, 9]. Among the Caucasians, the 
CYP1A1 variant was associated with a higher risk of breast cancer 
[10], whereas in Chinese and Japanese this polymorphism was 
associated with other types of cancer, such as lung cancer [11]. The 
frequency of the variant Val allele differs between Caucasian and 
Asians and is about 0.052 and 0.228, respectively [12].These amino 
acid substitutions in CYP1A1 are supposed to be the pathogenetic 
basis of increased susceptivity to certain diseases and altered drug 
metabolism[13].There were 68 coding ns SNP’s in CYP1A1 were 
characterized their functional impacts on disease susceptibility were 
also reported by means of Insilico studies[14].So we have taken 
those ns SNP’s as key factor for further studies on drug binding 
ability.2-(4-amino-3-methylphenyl) benzothiazole (DF 203, NSC 
674495) is metabolized in sensitive cancer cells can binds covalently 
to CYP1A1 induce expression and antiproliferative activity through 
DNA adduct formation[15]. Deleterious amino acid substitution in 
CYP1A1 protein may affect the binding ability of CYP1A1 with DF 
203 and have ability to interfere drug metabolism. So insights of 
these deleterious SNP’s would be beneficial to identify the basis of 
genetic variation and their response to therapy. 
MATERIALS AND METHODS 
Native and mutant models preparation and analysis 
Deleterious ns SNP’s were retrieved from dbSNP [16] based on 
literature studies [14] and then CYP1A1 native model was prepared 
using Homology modeling server Modeller 9v7 [17] for homology 
modeling of CYP1A1 sequence was retrieved from Uniprot database 
[http://www.uniprot.org/], Modeller9v7 implements homology 
modeling of proteins by satisfying spatial restraints, here we used 
4I8V as template an PDB structure resolved by X ray crystallography 
with 2.60 resolution. ClustalW was used to align the target and 
template sequences and the resultant alignment was stored as PIR 
format [18].The alignment and the template atom files were given as 
input to MODELLER 9v7, to generate the 3D structure of CYP1A1. 
The scripts “align-ligand.py” and “model-ligand.py” was used to 
generate ten rough 3D models. Modeller 9v7 automatically derives 
restraints from known related structures. The restraints include 
distances, angles, dihedral angles, pairs of dihedral angles, and some 
other spatial restraints. Bond and angle values are taken from 
CHARMM-22 [19] force field and then modeled structures were 
validated based on the backbone conformation of the ten models 
was inspected using the Phi/Psi Ramachandran plot given by 
PROCHECK server(http://nihserver.mbi.ucla.edu/SAVS/) and the 
results indicate that only one model out of ten generated models 
were perfectly fit with no residues in the disallowed region of 
Ramachandran plot [20].Then deleterious mutant models of CYP1A1 
were prepared using Pymol mutagenesis tool [21] and both native 
and mutant models were minimized using SWISSPDB server [22] 
then RMSD values were recorded for native and mutant 
models.Substitution of an amino acid may produce changes at the 
structural level. Changes in the secondary structure with respect to 
the substituted amino acid were analyzed using PDBsum [23]. 
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Drug binding affinity on native and mutant models 
Drug 2-(4-Amino-3-methylphenyl) benzothiazole (DF 203, NSC 
674495) binding affinity towards native and mutant models of 
CYP1A1 was analysed using autodock4 suite, and molecular docking 
tool [24]. Drug structure was retrived from PubChem compound 
database [25].Autodock uses Lamarckian Genetic Algorithm (LGA) 
to search the best conformers. Minimum docked free energy were 
calculated by AutoDock for each GA run and cluster ranking for total 
clusters were also reported by AutoDock. Docking modes were 
generally considered based on two factors: The ligand association 
with the key residues of the receptor and docked complex 
thermodynamic stability. Docking mode with lowest energy with 
satisfied above said parameters were selected from over 10 GA runs. 
The grid boxes were centered on the root of macromolecule.  
The intermolecular and intramolecular energy between the protein 
and the ligand calculated in docking simulations.To evaluate the 
candidate conformation, the grids were used as lookup tables which 
store the values used in the calculation, thus making the overall 
docking simulation exceptionally fast. The Graphical User Interface 
program ‘Auto Dock Tools’ was used to prepare, run, and analyze the 
docking simulations and Kollman united atom charges, solvation 
parameters, and polar hydrogens were added into the receptor PDB 
information for the preparation of protein in docking simulation 
finally Gasteiger charges were added in the ligand PDB file. Finally, 
the protein-ligand complexes were analyzed using DS Visualizer [26] 
and ligplot visualization tool [27]. 
Molecular Dynamics Simulation 
rs2229150 (R93W) considered for further dynamic simulation 
studies as they were showing, we then computed the comparative 
analysis of structural deviations in native and mutant structure. 
RMSD, RMSF, SAS and Rg analysis were carried out Molecular 
Dynamics simulation for the native CYP1A1 and mutant structures 
of nsSNP rs2229150 are done using Schrödinger11 Maestro-
Desmond package from the D. E. Shaw Research laboratory [28] free 
license is given to academic users for accessing Desmond and its 
source code. Desmond applies numerical techniques and parallel 
algorithms to attain specific and accurate performance on a platform 
that containing a number of processors, and also can be executed on 
a single-processor computer.  
Query ligand–protein complex immersed in TIP3P waterbox 
extending 10 Å marginal radius beyond any of the complex‘s atom 
by Desmond’s system builder. This step adds the counter ions to 
neutralize the simulation box and 0.15 M sodium and chloride ions 
were used to approximate physiological conditions. Then this 
complex was minimized to a convergence gradient threshold of 1.0 
kcal/ (mol.Å). Desmond dynamics program utilizes the OPLS2005 
force field and the NPT ensemble (constant number of particles, 
pressure and temperature) at 300 K, with default periodic boundary 
conditions. 5 ps were fixed for the production run. Once the 
simulation is Completed files saved as standard PDB files.  
Then these files were e analyzed using the component interactions 
script of Maestro [29] which does compute the native and mutant 
CYP1A1 models Molecular Dynamic Trajectory of RMSD, RMSF and 
Radius of gyration analysis and changes in energy, pressure and 
volume using simulation Quality Analyst [29]. 
RESULTS AND DISCUSSION 
Based on literature studies it was clear that six nsSNPs are having 
the ability to change protein stability, so here we have investigated 
their consequences on CYP1A1 protein. 
Modeling of Native and mutant models of CYP1A1 and Binding 
Site Prediction 
Experimentally resolved structure for CYP1A1 does not exist, so 
native CYP1A1 MODEL was generated using Modeller 9v7, using 
4I8V a crystallographic structure which has 512 amino acids and 
85% identity with the CYP1A1 sequence. The modeled structure is 
validated using SAVES PROCHECK, it generates the Ramachandran 
Plot. In that 89.50% residues are in most favored region and there is 
no residue present in disallowed region, this modeled native models. 
binding sites Arg106, Met121, Ser122, Trp131, Arg135, Leu142, 
Ile198, Asp313, Leu314, Phe315, Ala317, Gly318, Thr321, Val322, 
Ala325, Phe376, Phe381, Val382, Phe384, Thr385, Ile386, His388, 
Gln411 And Phe450 were predicted using the tool 3D Ligand 
site.Mutant of models building were carried out using PYMOL 
mutagenesis tool and minimized using Swiss PDB viewer saved in 
PDB format and visualized using by Pymol visualizer. 
  
 
Fig. 1: Modeled CYP1A structure validated using Ramachandran 
Plot 
 
Secondary Structure Analysis on Native and mutant models 
Deleterious nsSNPs of CYP1A1 changes its secondary structural 
organization and this alteration were analyzed in PDBsum and 
tabulated (Table 1).It has to be noted that the observed numbers of 
secondary structural elements are equal in both native and mutant 
models except the turns in all the six mutant models. 
Benzothiazoles (DF-203) binding affinity studies on native and 
mutant models of CYP1A1 using docking 
Based on in vitro studies the drug 2-(4-Amino-3-methylphenyl) 
benzothiazole (DF203, NSC 674495) active towards CYP1A1 protein 
and has the ability to lead the programmed cell death in cancerous 
cells. Substitution of deleterious amino acid in CYP1A1 protein may 
affect the binding ability of CYP1A1 with the drug molecules. This 
has to be analyzed to improve the potentiality of the drugs activity 
on CYP1A1 protein. Hence, we analyzed the binding ability of drugs 
with native and mutant models of CYP1A1 protein using Autodock4, 
and drug DF-203 and CYP1A1 interactions were depicted in 
LIGPLOT. The number of hydrogen bonds formed between protein 
and ligand were tabulated (Table 3).Van der Waals interacting 
energies and electrostatic interacting energies, binding energies, 
torsion free energy, internal energy between CYP1A1 protein (native 
and mutant) and DF-203 molecule were computed and tabulated 
(Table 2). 
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Table 1: Secondary Structure changes of Native and Mutant molecule studies 












Native  3  3  1  1  8  25  45  34  4  
rs2229150 
(R93W) 
3  3  1  1  8  25  45  35  4  
rs17861094(I78T ) 3  3  1  1  8  25  45  35  4  
rs34260157(R279G/W)  3  3  1  1  8  25  45  35  4  
rs45442501(R135W ) 3  3  1  1  8  25  45  35  4  
rs1048943 
(I462F ) 
3  3  1  1  8  25  44  35  4  
rs36121583(F470V ) 3  3  1  1  8  25  45  35  4  
 



















Native -6.36 -6.95 -0.04 -6.79 -0.18 0.6 
rs2229150 
(R93W) 
-6.12 -6.51 -0.01 -6.34 -0.17 0.55 
rs45442501 
(R135W ) 
-6.08 -6.46 -0.03 -6.31 -0.17 0.55 
rs34260157 
(R279G) 
-6.13 -6.51 -0.02 -6.34 -0.17 0.55 
rs34260157 
(R279W) 
-6.08 -6.46 -0.02 -6.28 -0.17 0.55 
rs17861094 
(I78T ) 
-5.94 -6.32 -0.03 -6.24 -0.17 0.55 
rs1048943 
(I462F ) 
-6.26 -6.00 -0.02 -6.20 -0.17 0.55 
rs36121583 
(F470V ) 
-5.94 -6.51 -0.04 -6.31 -0.17 0.55 
  
Table 3: DF203-CYP1A1 native and mutant H-Bond interactions 
Protein No of H bond Donor Acceptor H Bond distance 
Native 1 N2 O 3.28 
rs2229150 
(R93W) 
0 0 0 0 
rs45442501 
(R135W ) 
1 SG S 3.28 
rs34260157 
(R279G) 
1 N2 O 3.23 
rs34260157 
(R279W) 
1 N2 O 3.08 
rs17861094 
(I78T ) 
2 N2,SG O,S 3.28,3.20 
rs1048943 
(I462F ) 
1 N2 O 3.12 
rs36121583 
(F470V ) 
2 N2,SG O,S 3.24,3.20 
 
 
Fig. 2: CYP1A1 with DF203 
 
Fig. 3: R93W Mutant with DF203
 
 
   
   
Fig. 4: I78T, I462F, R135W, F470V, R279G, R279W Mutant models interaction with DF203 
 
  
Fig. 6: RMSD Plot of CYP1A1 native (R 93 W) Fig.7: RMSD Plot of mutant CYP1A1 
 
  
Fig. 8: RMSF Plot of CYP1A1 native CYP1A1 (R 93 W) Fig. 9: RMSF Plot of mutant 
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Fig. 10: Radius of gyration of Cα atoms of native and mutant CYP1A1 protein 
 
Fig. 11: Backbone RMSDs are shown as a function of time for native and mutant CYP1A1 
 
Molecular Dynamics Simulation 
Molecular simulation dynamics approach was used to compute 
RMSF, RMSD and Rg values of the deleterious mutant model 
(R93W)and native CYP1A1 and the results provided a diverged 
fashion of variation between native and mutant model (R93W) of 
CYP1A1.Generally RMSD for all the Ca atoms were calculated from 
the starting structure which was described as the central origin to 
compute the protein system and RMSF were calculated to plot the 
degree of flexibility in mutant due to that mutation curve differ from 
native CYP1A1 during the simulation.  
We observed a major fluctuation in both native and mutant between 
a time periods of 1000 to 5000 ps.Mutant CYP1A1 (R93W) structure 
showed deviation till 5000 ps from their starting structure and 
results in a backbone RMSD of ~0.74 to 0.27A
(Native is shown in red and mutant in blue). 
0
Genomic variants especially nsSNPs in the human genome needs 
insight knowledge because of their impact on cancer related studies 
and altered drug response of anticancer therapeutic agents. These 
deleterious nsSNP lead to alterations in protein function especially 
the geometric constraints, hydrophobicity and hydrogen bond 
formation [30, 31].Studies on nsSNPs effects towards protein 
stability revealed that approximately 25% of are deleterious and 
have altered protein function [32]. Wang and Moult reported that, 
the vast majority of the disease associated nsSNPs in their dataset 
(up to 80%) resulted in protein destabilization [33]. Molecular 
dynamics approach was used to gain the knowledge on native and 
mutant protein structure variation.Here the point mutation (R93W) 
which got altered drug response with 2-(4-Amino-3-methylphenyl) 
benzothiazole (DF203, NSC 674495) was considered for further MD 
studies and the Structural changes were analyzed using different 
parameters in 5ns simulation trajectory method. RMSD and RMSF 
data’s observed with fluctuation revealed the changes in molecular 
stability of native and R93W mutant CYP1A1 models. Thus, from the 
RMSD and RMSF analysis, it is confirmed reduced stability R93W 
would affect the CYP1A1 protein structure. Protein ligand 
interactions analysis using docking revealed that mutant models of 
CYP1A1 binding affinity is reduced with the drug DF-203,thus this 





The radius of gyration (Rg) is the mass-weighted root mean square 
distance of group of atoms from their common centre of mass so 
that it provided an observation into global dimension of protein. Radius 
of gyration graph for alpha-carbon atoms of protein vs time depicted in 
(Fig.11).  We observed a major fluctuation in both native and mutant 
between a time periods of 1000 to 5000 ns (Fig11) observation on Rg 
graph, native structure was found stable than mutant. 
Non synonymous single nucleotide polymorphisms (nsSNPs) are the 
known biomarkers to disease susceptibility. In conclusion, our 
results showed that the analysis of six different SNPs on the CYP1A1 
protein structure using Insilco. These point mutations can disturb 
CYP1A1 interactions with other molecules and the drugs. Current 
studies propose that a mutant R93W (rs2229150) out of 6nsSNPs 
like rs2229150, rs45442501, rs34260157, rs17861094, rs1048943, 
rs36121583 identified in this study constitute altered drug response 
and structure instability. Based molecular docking studies altered 
drug response was predicted for R93W mutant with DF-203(2-(4-
Amino-3-methylphenyl) benzothiazole) Structural consequences of 
the deleterious predicted point mutations have been extensively 
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using Molecular dynamics simulation approaches and based on 
various parameters like potential energy, root-mean-square 
deviation, and root-mean-square fluctuation and radiation gyration, 
it is observed that deleterious nsSNP at position R93W would play a 
significant role in causing disease by the CYP1A1 protein. Finally this 
theoretical approach is entirely based on Insilco approach would be 
helpful in reducing the cost in experimental depiction of pathological 
nsSNPs and CYP1A1 based drug design. 
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